Retrospective validation of the REVEAL 2.0 risk score with the Australian and New Zealand Pulmonary Hypertension Registry Cohort

James J. Anderson*, Edmund M. Lau, Melanie Lavender, Raymond Benza, David S. Celermajer, Nicholas Collins, Carolyn Corrigan, Nathan Dwyer, John Feenstra, Mark Horrigan, Dominic Keating, Fiona Kermeen, Eugene Kotlyar, Tanya McWilliams, Bronwen Rhodes, Peter Steele, Vivek Thakkar, Trevor Williams, Helen Whitford, Kenneth WhyteRobert Weintraub, Jeremy P. Wrobel, Anne Keogh, Geoff Strange

*Corresponding author for this work

    Research output: Contribution to journalArticlepeer-review

    21 Citations (Scopus)


    Background: Pulmonary arterial hypertension (PAH) prognosis has improved with targeted therapies; however, the long-term outlook remains poor. Objective multiparametric risk assessment is recommended to identify patients at risk of early morbidity and mortality, and for optimization of treatment. The US Registry to Evaluate Early and Long-Term PAH Disease Management (REVEAL) 2.0 risk score is a new model proposed for the follow-up of patients with PAH but has not been externally validated. Methods: The REVEAL 2.0 risk score was applied to a mixed prevalent and incident cohort of patients with PAH (n = 1,011) from the Pulmonary Hypertension Society of Australia and New Zealand (PHSANZ) Registry. Kaplan-Meier survival was estimated for each REVEAL 2.0 risk score strata and for a simplified three-category (low, intermediate, and high risk) model. Sensitivity analysis was performed on an incident-only cohort. Results: The REVEAL 2.0 model effectively discriminated risk in the large external PHSANZ Registry cohort, with a C statistic of 0.74 (both for full eight-tier and three-category models). When applied to incident cases only, the C statistic was 0.73. The three-category REVEAL 2.0 model demonstrated robust separation of 12- and 60-month survival estimates (all risk category comparisons P <.001). Although the full eight-tier REVEAL 2.0 model separated patients at low, intermediate, and high risk, survival estimates overlapped within some of the intermediate- and high-risk strata. Conclusions: The REVEAL 2.0 risk score was validated in a large external cohort from the PHSANZ Registry. The REVEAL 2.0 model can be applied for risk assessment of patients with PAH at follow-up. The simplified three-category model may be preferred for clinical use and for future comparison with other prognostic models.

    Original languageEnglish
    Pages (from-to)162-172
    Number of pages11
    Issue number1
    Publication statusPublished - Jan 2020


    • PAH
    • PAH risk prognostication
    • pulmonary arterial hypertension
    • REVEAL risk score


    Dive into the research topics of 'Retrospective validation of the REVEAL 2.0 risk score with the Australian and New Zealand Pulmonary Hypertension Registry Cohort'. Together they form a unique fingerprint.

    Cite this